Coronavirus (COVID-19)
Learn more
The purpose of this study is to assess the safety of the investigational drug zolbetuximab and to see if combining it with the drugs nab-paclitaxel and gemcitabine is safe and effective for treating metastatic pancreatic cancer. Zolbetuximab targets a protein called CLDN18.2, which is abundant on the surface of some pancreatic cancer cells. Zolbetuximab may help recruit immune cells to act against CLDN18.2, resulting in cancer cell death.
Eligibility Criteria:
This study is for patients age 18 and older.
Available at: Hartford Hospital, Hospital of Central Connecticut and MidState Medical Center.
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209